Genmab A/S
(NASDAQ : GMAB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
ABTAbbott Laboratories -1.14%105.640.8%$718.58m
TMOThermo Fisher Scientific, Inc. -2.08%420.131.0%$617.22m
MDTMedtronic Plc -3.92%103.380.6%$524.50m
ISRGIntuitive Surgical, Inc. -1.85%643.422.4%$431.45m
DHRDanaher Corp. -1.55%203.120.7%$406.00m
BDXBecton, Dickinson & Co. -1.67%228.021.0%$398.66m
INOInovio Pharmaceuticals, Inc. 3.38%17.575.9%$388.60m
QDELQuidel Corp. 4.94%198.677.7%$388.05m
DXCMDexCom, Inc. -0.43%387.627.9%$301.48m
BSXBoston Scientific Corp. -1.17%38.031.0%$272.07m
SYKStryker Corp. -2.10%202.061.3%$272.06m
VARVarian Medical Systems, Inc. -0.20%172.519.1%$271.65m
BAXBaxter International, Inc. -3.56%80.021.8%$243.03m
ALGNAlign Technology, Inc. -2.01%314.536.4%$222.54m
EWEdwards Lifesciences Corp. -3.52%80.280.4%$212.42m

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.